The Valley Desk

NCT03011034 · Interventional trial

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Overall registry status Completed

Phase 2

Conditions Myelodysplastic Syndromes

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov